To compare the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide 1.5 and 0.75 mg with glimepiride in East-Asian patients with type 2 diabetes (T2D).
| INTRODUCTION
The prevalence of type 2 diabetes (T2D) has been increasing at an alarming rate in East-Asian countries over recent decades. 1 A national epidemiological survey in 2010 on diabetes among Chinese adults revealed that the estimated overall prevalence of diabetes was 11.6%. 2 Faced with this huge population-based challenge, emerging antidiabetic agents must not only provide robust blood glucose (BG) control, but also enhance adherence to treatment and effectively prevent the micro-and macrovascular complications of diabetes. 3, 4 *Affiliation at the time of manuscript preparation: Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), with their unique pharmacological effects, including enhancement of insulin secretion in a glucose-dependent pattern, delay of gastric emptying and diminishment of appetite, have demonstrated efficacy with regard to glycated haemoglobin (HbA1c) reduction, with a lower risk of hypoglycaemia and weight loss. 4, 5 Importantly, significant cardiovascular benefits have been demonstrated in dedicated cardiovascular outcome studies of several GLP-1RAs with high homology. [6] [7] [8] These accumulated results suggest a better risk-to-benefit ratio of GLP1RAs compared with traditional antidiabetic drugs, such as glimepiride, which is currently widely used across East Asia. 9, 10 Dulaglutide, a once-weekly GLP-1RA approved for the treatment half-life of~5 days, making it suitable for once-weekly subcutaneous (s.c.) administration. 4, 11, 12 In phase II studies, dulaglutide demonstrated significant dosedependent improvements in glycaemic control and body weight, and a low rate of hypoglycaemia. 13, 14 In a completed global phase III study,
AWARD-3 (Assessment of Weekly AdministRation of Dulaglutide),
dulaglutide demonstrated significant HbA1c reductions as monotherapy, with both fasting and postprandial glucose improvements, and weight loss. 15 The present study is the first to examine the efficacy and safety of dulaglutide (0.75 and 1.5 mg) as monotherapy compared with glimepiride in East-Asian patients with T2D who had inadequate glycaemic control after treatment with lifestyle modifications and were either oral antihyperglycaemic medication (OAM)-naïve or on OAM monotherapy.
| MATERIALS AND METHODS

| Study design
This was a randomized, double-blind, double-dummy, parallel-arm, active comparator, non-inferiority phase III study conducted over 26 weeks at 48 centres in three East-Asian countries and regions (China, South Korea and Taiwan). The study consisted of four periods:
screening (2 weeks), lead-in (2 weeks; during which patients discontinued any previous OAMs), treatment (26 weeks), and a post-treatment safety follow-up (30 days; Figure S1 ). The study (ClinicalTrials.gov: NCT01644500) was conducted in accordance with the Declaration of Helsinki, 16 Good Clinical Practice guidelines, and applicable laws and regulations. The ethical review board approved the protocol before patient enrolment, and written informed consent was obtained from all patients. 
| Study participants
| Study treatment
Eligible patients were randomly assigned (1:1:1) to one of three double-blind groups according to a computer-generated random sequence using an interactive voice response system: once-weekly dulaglutide 
| Study endpoints
The primary efficacy endpoint was change in HbA1c from baseline at week 26 between once-weekly 1. 
| Statistical analyses
The study was designed with 90% power to confirm non-inferiority of A mixed-model repeated measure (MMRM) analysis using the mITT analysis set was used as the primary analysis, with change in HbA1c as the dependent variable, treatment, country or region, pre-study therapy, visit and treatment by visit interaction as fixed effects, baseline HbA1c as a covariate, and patient as a random effect.
The MMRM included HbA1c measurements from all post-baseline visits. Imputation of missing HbA1c data was not performed. Other efficacy and safety markers (continuous variables) were assessed using an MMRM model similar to that used for the primary analysis.
Categorical variables were assessed using Fisher's exact test from an analysis of variance model. TEAEs were coded using the Medical Dictionary for Regulatory Activities (version 19.1). Type 1 error was controlled for primary and gated secondary objectives. As per convention, P values <.05 were taken to indicate statistical significance, but that should be mostly interpreted as descriptive.
3 | RESULTS
| Patient disposition and baseline characteristics
Of 1150 patients screened, 737 eligible patients were randomized
(1:1:1) to one of three treatment groups. Overall, 61 patients discontinued the study, with 676 (91.7%) patients completing the study treatment ( Figure 1 ).
Patient demographics and baseline characteristics are described in Table 1 . A total of 54.3% of participants were men. The mean (Table S1 ).
Baseline characteristics were similar in the three treatment groups.
| Efficacy variables
Of the 737 patients randomized, 720 patients comprised the mITT population. At week 26, the least-squares mean (LSM; [SE]) change Figure 2A) . Overall, the HbA1c reduction with both doses of dulaglutide was non-inferior (P < .001) and superior (P < .001) to that achieved with glimepiride. Figure 2B shows LSM (SE) change in HbA1c by visit from baseline to week 26 in all treatment groups. The HbA1c reduction was significantly greater with both doses of dulaglutide compared with glimepiride in both OAMnaïve patients and those on OAM monotherapy (P < .05; Figure S2 ).
At week 26, a significantly greater proportion of patients in the dulaglutide 1.5 mg group compared with the glimepiride group achieved a decrease in HbA1c level to <53 mmol/mol or <7.0% (74.1% vs 57.4%; P < .001) and to ≤ 48 mmol/mol or ≤6.5% (59.4% vs 41.3%; P < .001).
The proportion of patients achieving HbA1c of <53 mmol/mol or ≤48 mmol/mol (<7% or ≤6.5%) at week 26 did not differ significantly between the dulaglutide 0.75 mg and glimepiride groups, although the proportion was numerically greater in the dulaglutide 0.75 mg group ( Figure 2C ). Abbreviations: BMI, body mass index; BP, blood pressure; bpm, beats per minute; HbA1c, glycated haemoglobin; N, total number of patients in specified treatment group; n, number of patients in specified category; OAM, oral antidiabetic medication; T2D, type 2 diabetes. compared with glimepiride at all time points (P < .001; Table S2 ).
Reductions in BG levels from baseline in 7-point SMBG were also significantly greater with dulaglutide 0.75 mg compared with glimepiride at morning 2-hour postprandial, midday 2-hour postprandial, evening 2-hour postprandial, and bed time assessments (all P < .05; Table S2 ).
Patients receiving dulaglutide 1.5 mg had greater reductions in the mean change of all 2-hour postprandial glucose (PPG) excursions compared with glimepiride (P < .001); while changes in evening 2-hour PPG excursions were similar between the dulaglutide 0.75 mg and glimepiride groups (P = .052). The decreases in morning (P = .017) and midday (P < .001) 2-hour PPG excursions were * P < .001 dulaglutide vs glimepiride. † P < .05 dulaglutide vs glimepiride. E, Seven-point self-monitored blood glucose (SMBG) profiles by time of day. PP, postprandial. *P < .001 dulaglutide vs glimepiride. † P < .05 dulaglutide vs glimepiride. F, Change in body weight from baseline to 26 weeks. *P < .001 dulaglutide vs glimepiride.
† P < .05 dulaglutide vs glimepiride. Abbreviation: SE, standard error significantly greater with dulaglutide 0.75 mg than with glimepiride (Table S2) .
At week 26, significantly greater increases in insulin-and C-peptide-based HOMA2 for β-cell function were observed with both dulaglutide groups compared with glimepiride (P < .05), and a significant decrease in C-peptide-based HOMA2 for insulin sensitivity was noticed in the dulaglutide 0.75 mg group (P = .007; Table S3 ).
| Safety and tolerability
Two of the 737 randomized patients did not receive the study drug (glimepiride) and were excluded from the safety analysis population.
Overall, 60.8% of patients (447/735) experienced at least 1 TEAE by the end of 26 weeks ( (Table 2) .
During the 26-week treatment period, 17 patients (2.3%) discontinued study treatment because of AEs ( Table 2 ). The incidence of TEAEs leading to discontinuation was similar among the three treatment groups (Table 2) .
During the 26-week treatment period, 13 patients (1.8%) reported SAEs; six patients (2.5%) in the dulaglutide 1.5 mg group, four patients (1.6%) in the dulaglutide 0.75 group, and three patients (1.2%) in the glimepiride group (Table S4) . One death occurred in the dulaglutide 0.75 mg group but was a result of intentional injury and was not considered to be related to the study drug ( Table 2 ).
The most frequently reported drug-related TEAEs corresponded to the gastrointestinal system organ class: diarrhoea (6.7%), nausea There were no cases of adjudicated acute or chronic pancreatitis during the study. At week 26, notably greater mean changes in p-amylase, total amylase and lipase were observed with dulaglutide compared with glimepiride (Table S5) . No patient in any group had pancreatic amylase and total amylase levels of >3 × the upper limit of normal at week 26, whereas three patients in each group had lipase levels of >3 × the upper limit of normal during the study ( Table 2 ).
The mean change in serum calcitonin levels was negligible in all three treatment groups during the 26-week treatment period. No cases of thyroid neoplasms, C-cell hyperplasia, or medullary thyroid carcinoma were reported during this study.
Twenty-five patients (5.1%) developed treatment-emergent dulaglutide ADAs at least once during the study. In 22 of these patients, no dulaglutide ADAs were observed at baseline but they developed ADAs post-baseline, with the highest titre being 1:64.
Two patients (one in each dulaglutide group) experienced mild urticaria. Of the 13 patients who reported hypersensitivity reactions, five patients (dulaglutide 1.5 mg, n = 1; dulaglutide 0.75 mg, n = 3; glimepiride, n = 1) had study drug-related hypersensitivity reactions.
None of these patients developed treatment-emergent dulaglutide ADAs.
| DISCUSSION
The present double-blind, double-dummy study showed that monotherapy with either dulaglutide 1.5 or 0.75 mg was associated with a significantly greater decrease from baseline in HbA1c than with glime- Abbreviations: AE, adverse event; N, number of patients in the analyses population in specified treatment arm; OAM, oral anti-hyperglycaemic medication; PG, plasma glucose; SAE, serious adverse event; TEAE, treatment-emergent adverse event; ULN, upper limit of normal.
*P ≤ .05 dulaglutide vs glimepiride. a P value is calculated based on Fisher's exact test.
b Lipid profile was measured at randomization (visit 3) for the first time with the TEAE collected from lead-in phase, leading to the high incidence of hyperlipidaemia.
c Overall P value is based on a negative binomial regression model: patient's hypoglycaemia count = OAM strata + treatment + country/region, with log of patient's total number of days of exposure/30 as an offset variable. The safety profile of dulaglutide in the present study is consistent with previous data from AWARD studies 15, [27] [28] [29] [30] 34, 35 and other compounds in the GLP-1RA class. 36, 37 The most common drug-related AEs reported in the present study were gastrointestinal (eg, diarrhoea or nausea), which were transient and rarely led to treatment discontinuation. A similar pattern of pancreatic enzyme increase associated with dulaglutide 15, [27] [28] [29] [30] 34, 35 and the GLP-1RA class of drugs 38 was also observed in the present study. Small elevations in the mean concentration of pancreatic enzymes within a normal range were observed over time. Several previous reports on GLP-1RAs have suggested that the elevation in pancreatic enzymes is not predictive of pancreatitis. 39 In the present study, no case of pancreatitis was reported by an investigator or adjudicated by an independent committee of expert physicians. The immunogenicity of dulaglutide was low, with 5.1% of patients developing treatment-emergent dulaglutide ADAs, which is lower than with other GLP-1RAs. 33 No systemic hypersensitivity reaction was reported. No new safety concerns were identified for dulaglutide in the present study beyond those previously described. 15, 35 The present study has some limitations. The short washout period of only 2 weeks, because of ethical considerations, is associated with unstable baseline HbA1c in patients taking OAMs before study entry, probably leading to an underestimation of HbA1c reduction from baseline in each single arm; however, our study primarily evaluated the treatment difference between dulaglutide and glimepiride, which is comparable with or without a washout period. The 26-week treatment period is relatively short for the assessment of glycaemic control considering the chronic nature of T2D. Prospective long-term studies are required to assess the durability of the observations noted in this study. Glimepiride 3 mg/d was set as the maximum dose in this study considering the early stage of T2D for eligible patients. Greater
HbA1c reduction might be achieved with a higher glimepiride dose, but previous studies have indicated that this could put patients at greater risk of hypoglycaemia with limited additional efficacy. [40] [41] [42] In conclusion, this 26-week double-blind study in East-Asian patients with T2D showed that both doses of once-weekly dulaglutide 
